Research in Dr. Balaz’s laboratory is oriented towards the development of experimental and computational methods for structure-based predictions of the rate and extent of processes which determine drug disposition and receptor binding. One of the goals of the research is to find ways to tailor drug structures to reduce the cytotoxicity of drugs, such as those used for treatment of some cancers or arthritis
Dr. Bergeron exploits mathematics, statistics, optimization and algorithms to discover interesting properties in datasets and generates models that generalize well to new samples. Current projects include optimizing the dose in radiotherapy cancer treatment planning and modeling various aspects of the drug design process.
Dr. Cen's research program focuses on the design and synthesis of molecular probes and therapeutic agents targeting epigenetic modifying enzymes. The ultimate goal is to translate these findings into novel treatments for cancers and age-related diseases.
Dr. Dearborn’s research focuses on development neurobiology in the fruit fly (Drosophila) in three primary areas: 1) The elucidation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor function during brain development; 2) Hedgehog (Hh)-dependent regulation of VDUP1 in cell proliferation; and 3) Molecular characterization of Eph receptor signaling pathways.
Dr. El-Fawal’s main research is focused in two broad areas: neurodegenerative and cardiopulmonary diseases. In particular, the Neurotoxicology laboratory is interested in the contribution of environmental chemicals - pesticides, heavy metals and solvents - to neurodegenerative disorders. The laboratory is also exploring the pulmonary and nervous system toxicity of ambient ultrafine particles and man-made nanoparticles.
Dr. Fandy's laboratory is involved in both basic and translational research in the field of molecular epigenetics. Specifically, his lab seeks to understand the mechanisms of action of the DNA methyltransferase (DNMT) inhibitors and how they induce clinical remission in hematological malignancies, examining questions such as can we predict who will respond to the drugs and can we make the therapy more effective?
Dr. Feleder has a long-standing interest in uncovering the mechanisms underlying the body's response to immune challenges, i.e., how the central nervous system controls the physiologic functions that protect the body from the harmful effects of infectious agents.
Dr. Glass's research uses numerous biochemical, molecular biology, and biophysical techniques to investigate the structure and functional role of chromatin reader domains in biological processes and in disease. Dr. Glass is currently engaged in a three-year NIH research grant that is seeking to identify new ways to prevent and treat Acute Myeloid Leukemia (AML).
Dr. Hass’ research integrates synthetic organic chemistry, pharmaceutical formulation and stability, biochemical assays, medicinal chemistry, and pharmacology. Her laboratory provides unique training opportunities for research students in the areas of drug synthesis, pharmaceutical formulation, topical drug delivery and assessment of drug efficacy.
Research in Dr. Ludeman’s lab is based on the application of synthetic and physical organic chemistry to investigations of drug design, metabolism, and delivery. One of her lab's current projects involves the synthesis and evaluation of a new class of drugs designed for targeted delivery to neuroblastoma and pheochromocytoma.
The long term research goal of Dr. Malik’s laboratory is to understand the host mediated mechanisms of innate immunity against intracellular bacterial pathogens. Over the past several years, her research has focused on elucidating the many complexities of innate immunity against Francisella tularensis, a category A biothreat agent.
Dr. Millington's research focuses on the function of opioid peptide neurons in mammalian brain and their role in pain perception, cardiovascular regulation, and addiction. The ultimate goal of this research is to develop novel treatments for the adverse effects of opiate analgesics, particularly addiction.
Professor, Vice Provost for Research
Chairman of ACPHS Pharmaceutical Research Institute
(518) 694-7397 | firstname.lastname@example.org
Program Affiliations: M.S. in Pharmaceutical Sciences, M.S. in Molecular Biosciences, M.S. in Health Outcomes Research
Dr. Mousa uses enabling technologies that include nanotechnology, biotechnology, and stem cells as key catalysts in the discovery of novel therapeutics and diagnostics for the treatment and prevention of various diseases including cancer, cardiovascular, neurological, ophthalmological, inflammatory, and other vascular disorders.
Dr. Musteata's research interests include the development of miniaturized analytical technology for pharmacokinetic studies and therapeutic drug monitoring, with the purpose of creating personalized therapeutic devices that integrate chemical analysis, decision, and drug delivery.
Dr. Parker’s research interests span the fields of health and health care, family, and social policy, examining the causes of social inequalities throughout the life course. Recent work has examined the inequalities in child health trajectories connected to parental resources, as well as a project related to the health of military women.
Dr. Polimeni's current research interests include healthcare financing in developing countries, energy efficiency and sustainability, economic development, transitional economies, transdisciplinary/ecological economics, transportation economics, and sustainable agriculture.
Dr. Shi's lab seeks to understand the molecular basis of disease pathogenesis by using advanced molecular biology, virology, molecular genetics, and bioinformatics approaches. Another major area of interest in the lab is the design and development of nucleic acid-based molecular diagnosis assays for detecting infectious diseases.
VDUP-1 (TBP-2) is a protein whose expression is decreased in tumors and increased following treatment with Vitamin D. Dr. Voigt is currently investigating the role of VDUP-1 in the regulation of transcription factor activity and cell proliferation/differentiation in different cell types.
Dr. Yager is testing the hypothesis that biological aging adversely impacts the ability of the NLRP3 inflammasome to properly regulate inflammation and host defense. Results from this work have the potential to facilitate the identification of new drug targets for the effective treatment of chronic inflammation and/or the development of new vaccination strategies for the elderly population.